Literature DB >> 8414414

Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial.

D H Char1, J M Quivey, J R Castro, S Kroll, T Phillips.   

Abstract

PURPOSE: Optimal radiation therapy for uveal melanoma is uncertain, and the relative efficacies of radioactive plaques and charged particles are unclear.
METHODS: The authors prospectively studied helium-ion irradiation and iodine 125 (125I) brachytherapy in a randomized, dynamically balanced trial. Of the 184 patients who met the eligibility criteria, 86 were treated with helium ions and 98 with 125I brachytherapy.
RESULTS: No patients with uveal melanoma had a history of systemic malignancy. Tumors were less than 15 mm in maximum diameter and less than 10 mm in thickness. A minimum tumor dose of 70 GyE was delivered to the tumor apex. There was a significantly higher local recurrence rate after 125I brachytherapy than after helium-ion irradiation. Enucleations occurred more frequently after brachytherapy (relative risk = 1.99; 95% confidence interval, 0.78-5.78). More anterior segment complications occurred after helium-ion irradiation. To date, there has been no measurable impact on survival.
CONCLUSIONS: Most uveal melanomas can be managed with radiation with retention of the eye. There was better tumor control with helium-ion irradiation; however, there were more anterior segment complications.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414414     DOI: 10.1016/s0161-6420(93)31446-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  37 in total

1.  A randomized, controlled trial of varying radiation doses in the treatment of choroidal melanoma.

Authors:  E S Gragoudas
Journal:  Trans Am Ophthalmol Soc       Date:  1998

2.  Where is the superiority of proton radiation for ocular tumours?

Authors:  Nikolaos E Bechrakis; Michael H Foerster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2002-07       Impact factor: 3.117

3.  Risk factors for residual and recurrent uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

Review 4.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

5.  Indications for trans-scleral local resection of uveal melanoma.

Authors:  B Damato; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-11       Impact factor: 4.638

6.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

7.  Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

Authors:  D H Char; S Kroll; J M Quivey; J Castro
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

8.  Risk factors for metastatic uveal melanoma after trans-scleral local resection.

Authors:  B E Damato; J Paul; W S Foulds
Journal:  Br J Ophthalmol       Date:  1996-02       Impact factor: 4.638

9.  Laser and proton radiation to reduce uveal melanoma-associated exudative retinal detachments.

Authors:  Devron H Char; Riley Bove; Theodore L Phillips
Journal:  Trans Am Ophthalmol Soc       Date:  2003

10.  Dosimetry and treatment planning of Occu-Prosta I-125 seeds for intraocular lesions.

Authors:  Suresh Chaudhari; Sudesh Deshpande; Vivek Anand; Sandeep De; Sanjay Saxena; A Dash; Mahua Basu; Preetam Samant; V Kannan
Journal:  J Med Phys       Date:  2008-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.